No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

Abstract

No evidence of subclinical JCV reactivation was found in our natalizumab treated MS patients up to 18 months of therapy, notwithstanding the marked increase in circulating B cells observed. Moreover, the efficacy of natalizumab, its tolerability and the positive impact on quality of life were confirmed in this study.